Asset Management One Co. Ltd. Acquires 1,779 Shares of STERIS plc (NYSE:STE)

Asset Management One Co. Ltd. lifted its holdings in shares of STERIS plc (NYSE:STE) by 1.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 101,685 shares of the medical equipment provider’s stock after acquiring an additional 1,779 shares during the period. Asset Management One Co. Ltd. owned approximately 0.10% of STERIS worth $24,620,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in STE. Massachusetts Financial Services Co. MA boosted its position in STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock worth $1,414,453,000 after purchasing an additional 778,613 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in STERIS by 7.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after purchasing an additional 120,616 shares during the period. Sustainable Growth Advisers LP boosted its stake in STERIS by 23.5% during the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after buying an additional 282,387 shares during the period. Impax Asset Management Group plc grew its holdings in shares of STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock worth $251,663,000 after purchasing an additional 263,383 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in STERIS by 0.9% in the 2nd quarter. Principal Financial Group Inc. now owns 1,017,888 shares of the medical equipment provider’s stock worth $223,467,000 after buying an additional 8,601 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity

In other news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at $139,493.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

STERIS Trading Up 0.3 %

STERIS stock opened at $225.82 on Tuesday. The business’s fifty day moving average is $233.54 and its 200 day moving average is $227.40. STERIS plc has a one year low of $195.47 and a one year high of $248.24. The stock has a market capitalization of $22.27 billion, a PE ratio of 56.03 and a beta of 0.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $1.98 by $0.16. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.00 EPS. On average, sell-side analysts predict that STERIS plc will post 9.02 EPS for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio is currently 56.58%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Stephens reiterated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Wednesday, August 7th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Wednesday, August 7th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Finally, KeyCorp raised their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.